Johnson & Johnson accused attorneys for people who have sued the pharmaceutical giant over the company’s talc products of sharing confidential documents with Reuters in what J&J called a “calculated effort” to try its subsidiary’s bankruptcy case in the press.

A U.S. judge said on Sept. 1 he would approve OxyContin maker Purdue Pharma LP’s bankruptcy reorganization plan, clearing a path to resolve thousands of opioid lawsuits and shielding the company’s wealthy Sackler family owners from future opioid litigation.

An alleged plan by Johnson & Johnson to spin off a company solely responsible for J&J’s talc-based products in order to mitigate lawsuit damages is still on the table following a ruling by a federal judge.

A settlement valued at $8.34 billion was reached between Purdue Pharmaand the Justice Department, which required the drug company to plead guilty to three felonies related to its marketing and distribution of OxyContin, according to the Wall Street Journal.

OxyContin maker Purdue Pharma LP reached a tentative agreement with some plaintiffs to resolve litigation over the company’s alleged role in fueling the U.S. opioid crisis and plans to tussle with states opposing the settlement offer in bankruptcy proceedings, people familiar with the matter said.